eurofins | Discovery Services

Certificate of Analysis

SGK3, active

(Recombinant enzyme expressed in Sf21 insect cells)
Item # 14-647, 14-647-K, 14-647M
Parent Lot # 1762413

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: *N*-terminal 6His-tagged, recombinant, human SGK3 amino acids 119–end, expressed by baculovirus in Sf21 insect cells. Purified using Ni^{2+}/NTA agarose. Purity 79.9% by SDS-PAGE and Coomassie blue staining. MW = 46.7kDa.

Specific Activity (Parent lot# 1762413): 2582U/mg, where one unit of SGK3, active activity is defined as 1nmol phosphate incorporated into Crosstide (GRPRTSSFAEGKK) per minute at 30°C with a final ATP concentration of 100µM.

Formulation: 0.653mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.

Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.

FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS

Quality Control Testing

Kinase Assay: 0.3–3.3ng of this lot of enzyme phosphorylated 250µM modified Crosstide (GRPRTSSFAEGKK) in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as SGK3 with the translated native sequence listed on page three.



SDS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of SGK3, active.

Eurofins Pharma Discovery Services UK Limited
Gemini Crescent
Dundee Technology Park
DUNDEE
DD2 1SW United Kingdom
T | +44 (0)1382 561600
F | +44 (0)1382 561601
www.eurofins.com/pharmadiscovery

Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Modified Crosstide (GRPRTSSFAEGKK):** Use a final assay concentration of 250µM. Make a 2.5mM stock. Add 2.5µl of stock per assay point.
3. **SGK3, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 0.3–3.3ng per assay point.
4. **[γ-^{33}P]ATP:** 2.5 x magnesium acetate/[γ-^{33}P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-^{33}P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5µl of 5 x reaction buffer per assay to wells
2. Add 2.5µl of **modified Crosstide (GRPRTSSFAEGKK)**.
3. Add **2.5µl (0.3–3.3ng) SGK3, active**.
4. Add 5µl of dH_2O.
5. Add 10µl of diluted [γ-^{33}P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5µl of 3% phosphoric acid.
8. Transfer a 10µl aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1µl of 30% phosphoric acid.

eurofins | Discovery Services

Certificate of Analysis

SGK3 Sequence Information

Protein human SGK3

Tag N Terminal 6His

Native sequence M31 of the recombinant protein is equivalent to M119 of human SGK3

Accession number GenBank NM_013257

Recombinant SGK3 amino acid sequence:

```
   1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MDSPKHQSDP SEDEDERSSQ KLHSTSQNIN
  61 LGPSGNPHAK PTDFDFLKVI GKGSFGKVLL AKRKLDGKFY AVKVLQKKIV LNRKEQKHIM
 121 AERNVLLKNV KHPFLVGLHY SFQTTEKLYF VLDFVNGGEL FFHLQRERSF PEHRARFYAA
 181 EIASALGYLH SIKIVYRDLK PENILLDSVG HVVLTDFGLC KEGIAISDTT TTFCGTPEYL
 241 APEVIRKQPY DNTVDWWCLG AVLYEMLYGL PPFYCRDVAE MYDNILHKPL SLRPGVSLTA
 301 WSILEELLEK DRQNRLGAKE DFLEIQNHPF FESLSWADLV QKKIPPPFNP NVAGPDDIRN
 361 FDTAFTEETV PYSVCVSSDY SIVNASVLEA DDAFVGFSYA PPSEDLFL
```

Recombinant SGK3 nucleotide sequence:

```
   1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
  61 tattttcagg gcgccatgga tccggaattc atggacagtc caaaacacca gtcagatcca
 121 tctgaagatg aggatgaaag aagttctcag aagctacact ctacctcaca gaacatcaac
 181 ctgggaccgt ctggaaatcc tcatgccaaa ccaactgact ttgatttctt aaaagttatt
 241 ggaaaaggca gctttggcaa ggttcttctt gcaaaacgga aactggatgg aaaattttat
 301 gctgtcaaag tgttacagaa aaaaatagtt ctcaacagaa aagagcaaaa acatattatg
 361 gctgaacgta atgtgctctt gaaaaatgtg aaacatccgt ttttggttgg attgcattat
 421 tccttccaaa caactgaaaa gctttatttt gttctggatt ttgttaatgg aggggagctt
 481 tttttccact tacaaagaga acggtccttt cctgagcaca gagctaggtt ttacgctgct
 541 gaaattgcta gtgcattggg ttacttacat tccatcaaaa tagtatacag agacttgaaa
 601 ccagaaaata ttcttttgga ttcagtagga catgttgtct taacagattt tgggctttgt
 661 aaagaaggaa ttgctatttc tgacaccact accacatttt gtgggacacc agagtatctt
 721 gcacctgaag taattagaaa acagccctat gacaatactg tagattggtg gtgccttggg
 781 gctgttctgt atgaaatgct gtatggattg cctccttttt attgccgaga tgttgctgaa
 841 atgtatgaca atatccttca caaaccccta agtttgaggc caggagtgag tcttacagcc
 901 tggtccattc tggaagaact cctagaaaaa gacaggcaaa atcgacttgg tgccaaggaa
 961 gactttcttg aaattcagaa tcatcctttt tttgaatcac tcagctgggc tgaccttgta
1021 caaaagaaga ttccaccacc atttaatcct aatgtggctg gaccagatga tatcagaaac
1081 tttgacacag catttacaga agaaacagtt ccatattctg tgtgtgtatc ttctgactat
1141 tctatagtga atgccagtgt attggaggca gatgatgcat tcgttggttt ctcttatgca
1201 cctccttcag aagacttatt tttgtga
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 **Eurofins Pharma Discovery Services UK Limited** is an independent member of Eurofins Discovery Services